Atomo Diagnostics (ASX: AT1) is rapidly building out its diagnostics pipeline

14 May 2025: We spoke with John Kelly, CEO of Atomo Diagnostics (ASX: AT1) about the company's progress with its new syphilis diagnostic and the building out of its diagnostics pipeline. We also talked about AT1's continued success with its core HIV diagnostic franchise. Atomo's diagnostics are highly differentiated from the current standard of care, increasing the coming commercial payoff.